Advanced search
Publication Cover
OncoImmunology Volume 10, 2021 - Issue 1
Submit an article Journal homepage
4,497
Views
12
CrossRef citations to date
0
Altmetric
Original Research

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors

Pierre Dillarda Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, NorwayORCID Iconhttps://orcid.org/0000-0002-4812-9159View further author information
ORCID Icon,
Nicholas Caseya Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, NorwayORCID Iconhttps://orcid.org/0000-0001-6706-8710View further author information
ORCID Icon,
Sylvie Pollmanna Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, NorwayView further author information
,
Patrik Vernhoffa Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, NorwayView further author information
,
Gustav Gaudernackb Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, NorwayORCID Iconhttps://orcid.org/0000-0002-9678-7447View further author information
ORCID Icon,
Gunnar Kvalheima Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, NorwayView further author information
,
Sébastien Wälchlia Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, NorwayCorrespondence[email protected]
View further author information
&
Else Marit Inderberga Translational Research Unit, Department of Cellular Therapy, Oslo University Hospital, Oslo, NorwayCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6147-3536View further author information
ORCID Icon show all
Article: 1936757 | Received 12 Oct 2020, Accepted 26 May 2021, Published online: 17 Jun 2021

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Jenny Sprooten, Raquel S. Laureano, Isaure Vanmeerbeek, Jannes Govaerts, Stefan Naulaerts, Daniel M. Borras, Lisa Kinget, Jitka Fucíková, Radek Špíšek, Lenka Palová Jelínková, Oliver Kepp, Guido Kroemer, Dmitri V. Krysko, An Coosemans, Rianne D.W. Vaes, Dirk De Ruysscher, Steven De Vleeschouwer, Els Wauters, Evelien Smits, Sabine Tejpar, Benoit Beuselinck, Sigrid Hatse, Hans Wildiers, Paul M. Clement, Peter Vandenabeele, Laurence Zitvogel & Abhishek D. Garg. (2023) Trial watch: chemotherapy-induced immunogenic cell death in oncology. OncoImmunology 12:1.
Read now

Articles from other publishers (11)

Javier Torres-Jiménez, Javier Baena Espinar, Helena Bote de Cabo, María Zurera Berjaga, Jorge Esteban-Villarrubia, Jon Zugazagoitia Fraile & Luis Paz-Ares. (2024) Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments. Drugs.
Crossref
Chenwei Wang, Jiewen Chen, Jingyao Li, Zhihong Xu, Lihong Huang, Qian Zhao, Lei Chen, Xiaolong Liang, Hai Hu, Gang Li, Chengjie Xiong, Bin Wu, Hua You, Danyi Du, Xiaoling Wang, Hongle Li, Zibing Wang & Lin Chen. (2024) An EBV-related CD4 TCR immunotherapy inhibits tumor growth in an HLA-DP5+ nasopharyngeal cancer mouse model. Journal of Clinical Investigation 134:8.
Crossref
Dandan Yang, Zhihui Duan, Ping Yuan, Chengming Ding, Xiaoming Dai, Guodong Chen & Daichao Wu. (2023) How does TCR-T cell therapy exhibit a superior anti-tumor efficacy. Biochemical and Biophysical Research Communications 687, pages 149209.
Crossref
Saborni Chattopadhyay, Yu-Pei Liao, Xiang Wang & André E. Nel. (2023) Use of Stromal Intervention and Exogenous Neoantigen Vaccination to Boost Pancreatic Cancer Chemo-Immunotherapy by Nanocarriers. Bioengineering 10:10, pages 1205.
Crossref
Sahana Jayaraman, Janelle M. Montagne, Thomas R. Nirschl, Emily Marcisak, Jeanette Johnson, Amanda Huff, Meng-Hsuan Hsiao, Julie Nauroth, Thatcher Heumann, Jelani C. Zarif, Elizabeth M. Jaffee, Nilo Azad, Elana J. Fertig, Neeha Zaidi & H. Benjamin Larman. (2023) Barcoding intracellular reverse transcription enables high-throughput phenotype-coupled T cell receptor analyses. Cell Reports Methods 3:10, pages 100600.
Crossref
Qi Ai, Fanlu Li, Siyi Zou, Zehui Zhang, Yangbing Jin, Lingxi Jiang, Hao Chen, Xiaxing Deng, Chenghong Peng, Nan Mou, Chenlei Wen, Baiyong Shen & Qian Zhan. (2023) Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors. Frontiers in Immunology 14.
Crossref
Yunkai Yang, Huan Zhang, Shanshan Huang & Qian Chu. (2023) KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration. Journal of Clinical Medicine 12:2, pages 709.
Crossref
Shumei Kato, Yu Fujiwara & David S. Hong. (2022) Targeting KRAS : Crossroads of Signaling and Immune Inhibition . Journal of Immunotherapy and Precision Oncology 5:3, pages 68-78.
Crossref
Laura Mosca, Alessandra de Angelis, Andrea Ronchi, Annarosaria De Chiara, Flavio Fazioli, Carlo Ruosi, Lucia Altucci, Mariarosaria Conte & Filomena de Nigris. (2022) Sarcoma Common MHC-I Haplotype Restricts Tumor-Specific CD8+ T Cell Response. Cancers 14:14, pages 3414.
Crossref
Suzanne Quinn, Natasha Lenart, Victoria Dronzek, Gina M. Scurti, Nasheed M. Hossain & Michael I. Nishimura. (2022) Genetic Modification of T Cells for the Immunotherapy of Cancer. Vaccines 10:3, pages 457.
Crossref
Elena Corral de la Fuente, Maria Eugenia Olmedo Garcia, Ana Gomez Rueda, Yolanda Lage & Pilar Garrido. (2022) Targeting KRAS in Non-Small Cell Lung Cancer. Frontiers in Oncology 11.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.